Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
mi
from
Lincoln, NE
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
mi
from
East Orange, NJ
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
mi
from
East Orange, NJ
Click here to add this to my saved trials
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
mi
from
Raleigh, NC
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
mi
from
Akron, OH
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
mi
from
Pawtucket, RI
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
mi
from
Pawtucket, RI
Click here to add this to my saved trials
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
mi
from
Corpus Christi, TX
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
mi
from
La Jolla, CA
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated:  9/8/2015
mi
from
Buenos Aires,
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status: Enrolling
Updated: 9/8/2015
mi
from
Buenos Aires,
Click here to add this to my saved trials
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
Status: Enrolling
Updated:  9/8/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
Status: Enrolling
Updated: 9/8/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
Status: Enrolling
Updated:  9/9/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
Status: Enrolling
Updated: 9/9/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
Status: Enrolling
Updated:  9/9/2015
Washington University School of Medicine
mi
from
St. Louis, MO
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
Status: Enrolling
Updated: 9/9/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
Status: Enrolling
Updated:  9/9/2015
Nebraska Methodist Hospital
mi
from
Omaha, NE
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
Status: Enrolling
Updated: 9/9/2015
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
Status: Enrolling
Updated:  9/9/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
Status: Enrolling
Updated: 9/9/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)
Status: Enrolling
Updated:  9/9/2015
University of California at San Francisco
mi
from
San Francisco, CA
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)
Status: Enrolling
Updated: 9/9/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine
Status: Enrolling
Updated:  9/9/2015
University of Michigan
mi
from
Ann Arbor, MI
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine
Status: Enrolling
Updated: 9/9/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine
Status: Enrolling
Updated:  9/9/2015
University of Michigan University Hospital
mi
from
Ann Arbor, MI
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine
Status: Enrolling
Updated: 9/9/2015
University of Michigan University Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
External Immobilization Compared to Limited Immobilization Using a Novel Real-time Localization System of the Prostate
Status: Enrolling
Updated:  9/9/2015
Madigan Healthcare System
mi
from
Tacoma, WA
External Immobilization Compared to Limited Immobilization Using a Novel Real-time Localization System of the Prostate
Status: Enrolling
Updated: 9/9/2015
Madigan Healthcare System
mi
from
Tacoma, WA
Click here to add this to my saved trials
Reduced Planning Target Volume (PTV) Margins for the Treatment of Prostate Cancer Using the Calypso 4D Localization System
Reduced PTV Margins for the Treatment of Prostate Cancer With IMRT Using Real-Time, State-of-the-Art Motion Tracking With the Calypso 4D Localization System: A Feasibility Study
Status: Enrolling
Updated:  9/9/2015
Madigan Healthcare System
mi
from
Tacoma, WA
Reduced Planning Target Volume (PTV) Margins for the Treatment of Prostate Cancer Using the Calypso 4D Localization System
Reduced PTV Margins for the Treatment of Prostate Cancer With IMRT Using Real-Time, State-of-the-Art Motion Tracking With the Calypso 4D Localization System: A Feasibility Study
Status: Enrolling
Updated: 9/9/2015
Madigan Healthcare System
mi
from
Tacoma, WA
Click here to add this to my saved trials
Daily Target Guided Radiation Therapy Using the Calypso 4D Localization System in Patients Who Have Had a Prostatectomy for Prostate Cancer
Post-prostatectomy Daily Target Guided Radiotherapy Using Real-Time, State-of-the-Art Motion Tracking With the Calypso 4D Localization System: A Feasibility Study
Status: Enrolling
Updated:  9/9/2015
Madigan Healthcare System
mi
from
Tacoma, WA
Daily Target Guided Radiation Therapy Using the Calypso 4D Localization System in Patients Who Have Had a Prostatectomy for Prostate Cancer
Post-prostatectomy Daily Target Guided Radiotherapy Using Real-Time, State-of-the-Art Motion Tracking With the Calypso 4D Localization System: A Feasibility Study
Status: Enrolling
Updated: 9/9/2015
Madigan Healthcare System
mi
from
Tacoma, WA
Click here to add this to my saved trials
Low-Fat Fish Oil Diet for Prostate Cancer Prevention
Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer
Status: Enrolling
Updated:  9/9/2015
West Los Angeles VA
mi
from
Los Angeles, CA
Low-Fat Fish Oil Diet for Prostate Cancer Prevention
Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer
Status: Enrolling
Updated: 9/9/2015
West Los Angeles VA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Low-Fat Fish Oil Diet for Prostate Cancer Prevention
Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer
Status: Enrolling
Updated:  9/9/2015
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Low-Fat Fish Oil Diet for Prostate Cancer Prevention
Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer
Status: Enrolling
Updated: 9/9/2015
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease
Status: Enrolling
Updated:  9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease
Status: Enrolling
Updated: 9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression
Status: Enrolling
Updated:  9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression
Status: Enrolling
Updated: 9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.
Status: Enrolling
Updated:  9/10/2015
Cedars Sinai Medical Center SC
mi
from
Los Angeles, CA
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.
Status: Enrolling
Updated: 9/10/2015
Cedars Sinai Medical Center SC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.
Status: Enrolling
Updated:  9/10/2015
Hackensack University Medical Center Hackensack Univ
mi
from
Hackensack, NJ
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.
Status: Enrolling
Updated: 9/10/2015
Hackensack University Medical Center Hackensack Univ
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.
Status: Enrolling
Updated:  9/10/2015
Novartis Investigative Site
mi
from
Brussels,
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.
Status: Enrolling
Updated: 9/10/2015
Novartis Investigative Site
mi
from
Brussels,
Click here to add this to my saved trials
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated:  9/10/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated: 9/10/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated:  9/11/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated: 9/11/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Molecular and Genetic Changes in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Cisplatin and Alimta - Phase II Study
Status: Enrolling
Updated:  9/11/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Molecular and Genetic Changes in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Cisplatin and Alimta - Phase II Study
Status: Enrolling
Updated: 9/11/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  9/14/2015
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 9/14/2015
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer
Feasibility Study of Stereotactic Body Radiation Therapy Followed by Wedge Resection for Peripherally Located Early Stage Non-small Cell Lung Cancer
Status: Enrolling
Updated:  9/14/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer
Feasibility Study of Stereotactic Body Radiation Therapy Followed by Wedge Resection for Peripherally Located Early Stage Non-small Cell Lung Cancer
Status: Enrolling
Updated: 9/14/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.
A Phase II Randomized Study of Nab-paclitaxel With Gemcitabine at Two Different Dose Combinations to Determine Efficacy in Patients With Advanced Non- Squamous Non-small Cell Lung Cancer (NSCLC).
Status: Enrolling
Updated:  9/14/2015
West Virginia University Hospitals Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.
A Phase II Randomized Study of Nab-paclitaxel With Gemcitabine at Two Different Dose Combinations to Determine Efficacy in Patients With Advanced Non- Squamous Non-small Cell Lung Cancer (NSCLC).
Status: Enrolling
Updated: 9/14/2015
West Virginia University Hospitals Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Boulder Community Hospital
mi
from
Boulder, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Anthony Central Hospital
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Anthony Central Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Porter Adventist Hospital
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Joseph Hospital
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Rose Medical Center
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Swedish Medical Center
mi
from
Englewood, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
mi
from
Grand Junction, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
mi
from
Grand Junction, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
North Colorado Medical Center
mi
from
Greeley, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
North Colorado Medical Center
mi
from
Greeley, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Hope Cancer Care Center at Longmont United Hospital
mi
from
Longmont, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Hope Cancer Care Center at Longmont United Hospital
mi
from
Longmont, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
McKee Medical Center
mi
from
Loveland, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
McKee Medical Center
mi
from
Loveland, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials